MARKET

IMVT

IMVT

Immunovant Inc
NASDAQ
29.06
+0.12
+0.41%
After Hours: 29.00 -0.06 -0.21% 19:55 05/11 EDT
OPEN
28.94
PREV CLOSE
28.94
HIGH
30.16
LOW
28.64
VOLUME
1.15M
TURNOVER
--
52 WEEK HIGH
30.16
52 WEEK LOW
13.52
MARKET CAP
5.91B
P/E (TTM)
-10.8320
1D
5D
1M
3M
1Y
5Y
1D
Immunovant to report fourth-quarter, fiscal-year results, give business update on conference call
PUBT · 3h ago
Weekly Report: what happened at IMVT last week (0504-0508)?
Weekly Report · 14h ago
Weekly Report: what happened at IMVT last week (0427-0501)?
Weekly Report · 05/04 09:22
Immunovant director Robert Graham Susman sells 2,502 shares for $67,988.34
PUBT · 05/01 22:40
Analysts’ Top Healthcare Picks: Sandoz Group Ltd (SDZXF), Immunovant (IMVT)
TipRanks · 04/27 17:50
Weekly Report: what happened at IMVT last week (0420-0424)?
Weekly Report · 04/27 09:23
Insiders Dump Shares in Global-e, EyePoint, Immunovant, Nerdy, Argan
TipRanks · 04/25 13:01
Top Immunovant Executives Make Major Moves With Their Own Shares
TipRanks · 04/25 02:02
More
About IMVT
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).

Webull offers Immunovant Inc stock information, including NASDAQ: IMVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMVT stock methods without spending real money on the virtual paper trading platform.